IR Notice

Announcement

2022 Closing Announcement of FY2022

2022 Closing Announcement of FY2022 pc
 

Closing Announcement of FY2022

CONSILIDATED STATEMENTS OF FINANCIAL POSITION

As of December 31, 2022

(Unit : KRW)

Information on the subject, amount, and amount of the statement of financial position of the settlement announcement

Details of the statement of financial position of the settlement

Account Amount Account Amount
ASSETS LIABILITIES
1. CURRENT ASSETS 6,457,656,567,077 1. CURRENT LIABILITIES 4,181,541,561,220
Cash and cash equivalents 890,819,570,657 Trade and other current payables 1,761,600,070,367
Short-term financial instruments 2,168,901,000,000 Emission liability 538,848,000
Financial assets at fair value through 98,505,711,790 Debentures and borrowings 1,138,800,019,346
Trade and other receivables 732,839,221,107 Contract liabilities 68,530,178,265
Inventories 2,375,818,961,320 Lease liabilities 142,247,057,483
Contract assets 87,316,397,189 Current tax liabilities 223,298,677,221
Other current financial assets 48,789,472,350 Other current liabilities 846,526,710,538
Other current assets 54,666,232,664
Ⅱ. NON-CURRENT LIABILITIES 3,416,034,302,109
Trade and other payables 551,366,868,613
Debentures and borrowings 965,090,332,157
Deribative liabilities 22,733,991,336
Contract liabilities 318,360,573,185
Lease liabilities 267,895,530,480
Ⅱ. NON-CURRENT ASSETS 10,124,393,691,409 Deferrde tax liabilities 1,214,215,655,517
Long-term financial instruments 7,335,813,270 Other non-current liabilities 76,371,350,821
Trade and other receivables 4,428,344,378
Investments in associate and joint venture 30,774,605,702 TOTAL LIABILITIES 7,597,575,863,329
Property, pant and equipment 3,416,528,836,940
Intangible assets 5,961,306,684,591 EQUITY
Right-of-use assets 454,923,496,204 Share capial 177,935,000,000
Defined beneift asset 29,646,230,762 Share premium 5,663,111,352,594
Contract assets 177,626,602,866 Accumulated other comprehensive loss (2,173,393,264)
Other non-current financial assets 322,091,698,923 Retained earnings 3,145,601,435,827
Other non-current assets 3,524,720,204
TOTAL EQUITY 8,984,474,395,157
TOTAL ASSETS 16,582,050,258,486 TOTAL LIABILITIES AND EQUITY 16,582,050,258,486

March 17, 2023

SAMSUNG BIOLOGICS CO., LTD

president & CEO John Rim

The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.

Samil PricewaterhouseCoopers CEO Soonsoo Yoon

Closing Announcement of FY2022

SEPARATE STATEMENTS OF FINANCIAL POSITION

As of December 31, 2022

(Unit : KRW)

Information on the subject, amount, and amount of the statement of financial position of the settlement announcement

Details of the statement of financial position of the settlement

Account Amount Account Amount
ASSETS LIABILITIES
1. CURRENT ASSETS 4,919,357,578,500 1. CURRENT LIABILITIES 2,990,676,467,009
Cash and cash equivalents 757,945,988,143 Trade and other current payables 1,628,734,131,092
Short-term financial instruments 2,168,901,000,000 Emission liability 538,848,000
Financial assets at fair value through 98,505,711,790 Debentures and borrowings 517,997,721,221
Trade and other receivables 503,997,178,409 Contract liabilities 64,204,826,542
Inventories 1,243,171,975,151 Lease liabilities 140,991,867,493
Contract assets 95,823,666,322 Current tax liabilities 187,319,244,039
Other current financial assets 37,047,599,149 Other current liabilities 450,889,828,622
Other current assets 13,964,459,536
Ⅱ. NON-CURRENT LIABILITIES 1,878,559,194,238
Trade and other payables 542,653,723,715
Debentures and borrowings 765,090,332,157
Deribative liabilities 22,733,991,336
Contract liabilities 225,477,213,506
Ⅱ. NON-CURRENT ASSETS 7,246,481,301,027 Lease liabilities 266,232,582,703
Long-term financial instruments 5,187,000,000 Other non-current liabilities 76,371,350,821
Investments in subsidiary, sccociate and joint 3,308,792,565,514 TOTAL LIABILITIES 4,869,235,661,247
Property, pant and equipment 3,083,545,436,767
Intangible assets 39,436,621,913 EQUITY
Right-of-use assets 451,792,929,789 Share capial 177,935,000,000
Defined beneift asset 28,625,478,854 Share premium 5,672,425,121,121
Contract assets 208,515,931,997 Accumulated other comprehensive loss (6,726,079,112)
Deferred tax assets 82,270,164,199 Retained earnings 1,452,969,176,271
Other non-current financial assets 25,954,612,332
Other non-current assets 1,725,557,715 TOTAL EQUITY 7,296,603,218,280
TOTAL ASSETS 12,165,838,879,527 TOTAL LIABILITIES AND EQUITY 12,165,838,879,527

March 17, 2023

SAMSUNG BIOLOGICS CO., LTD

president & CEO John Rim

The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.

Samil PricewaterhouseCoopers CEO Soonsoo Yoon

2022 Closing Announcement of FY2022 mo
 

Closing Announcement of FY2022

CONSILIDATED STATEMENTS OF FINANCIAL POSITION

As of December 31, 2022

(Unit : KRW)

Information on the subject, amount, and amount of the statement of financial position of the settlement announcement

Details of the statement of financial position of the settlement

Account Amount Account Amount
ASSETS LIABILITIES
1. CURRENT ASSETS 6,457,656,567,077 1. CURRENT LIABILITIES 4,181,541,561,220
Cash and cash equivalents 890,819,570,657 Trade and other current payables 1,761,600,070,367
Short-term financial instruments 2,168,901,000,000 Emission liability 538,848,000
Financial assets at fair value through 98,505,711,790 Debentures and borrowings 1,138,800,019,346
Trade and other receivables 732,839,221,107 Contract liabilities 68,530,178,265
Inventories 2,375,818,961,320 Lease liabilities 142,247,057,483
Contract assets 87,316,397,189 Current tax liabilities 223,298,677,221
Other current financial assets 48,789,472,350 Other current liabilities 846,526,710,538
Other current assets 54,666,232,664
Ⅱ. NON-CURRENT LIABILITIES 3,416,034,302,109
Trade and other payables 551,366,868,613
Debentures and borrowings 965,090,332,157
Deribative liabilities 22,733,991,336
Contract liabilities 318,360,573,185
Lease liabilities 267,895,530,480
Ⅱ. NON-CURRENT ASSETS 10,124,393,691,409 Deferrde tax liabilities 1,214,215,655,517
Long-term financial instruments 7,335,813,270 Other non-current liabilities 76,371,350,821
Trade and other receivables 4,428,344,378
Investments in associate and joint venture 30,774,605,702 TOTAL LIABILITIES 7,597,575,863,329
Property, pant and equipment 3,416,528,836,940
Intangible assets 5,961,306,684,591 EQUITY
Right-of-use assets 454,923,496,204 Share capial 177,935,000,000
Defined beneift asset 29,646,230,762 Share premium 5,663,111,352,594
Contract assets 177,626,602,866 Accumulated other comprehensive loss (2,173,393,264)
Other non-current financial assets 322,091,698,923 Retained earnings 3,145,601,435,827
Other non-current assets 3,524,720,204
TOTAL EQUITY 8,984,474,395,157
TOTAL ASSETS 16,582,050,258,486 TOTAL LIABILITIES AND EQUITY 16,582,050,258,486

March 17, 2023

SAMSUNG BIOLOGICS CO., LTD

president & CEO John Rim

The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.

Samil PricewaterhouseCoopers CEO Soonsoo Yoon

Closing Announcement of FY2022

SEPARATE STATEMENTS OF FINANCIAL POSITION

As of December 31, 2022

(Unit : KRW)

Information on the subject, amount, and amount of the statement of financial position of the settlement announcement

Details of the statement of financial position of the settlement

Account Amount Account Amount
ASSETS LIABILITIES
1. CURRENT ASSETS 4,919,357,578,500 1. CURRENT LIABILITIES 2,990,676,467,009
Cash and cash equivalents 757,945,988,143 Trade and other current payables 1,628,734,131,092
Short-term financial instruments 2,168,901,000,000 Emission liability 538,848,000
Financial assets at fair value through 98,505,711,790 Debentures and borrowings 517,997,721,221
Trade and other receivables 503,997,178,409 Contract liabilities 64,204,826,542
Inventories 1,243,171,975,151 Lease liabilities 140,991,867,493
Contract assets 95,823,666,322 Current tax liabilities 187,319,244,039
Other current financial assets 37,047,599,149 Other current liabilities 450,889,828,622
Other current assets 13,964,459,536
Ⅱ. NON-CURRENT LIABILITIES 1,878,559,194,238
Trade and other payables 542,653,723,715
Debentures and borrowings 765,090,332,157
Deribative liabilities 22,733,991,336
Contract liabilities 225,477,213,506
Ⅱ. NON-CURRENT ASSETS 7,246,481,301,027 Lease liabilities 266,232,582,703
Long-term financial instruments 5,187,000,000 Other non-current liabilities 76,371,350,821
Investments in subsidiary, sccociate and joint 3,308,792,565,514 TOTAL LIABILITIES 4,869,235,661,247
Property, pant and equipment 3,083,545,436,767
Intangible assets 39,436,621,913 EQUITY
Right-of-use assets 451,792,929,789 Share capial 177,935,000,000
Defined beneift asset 28,625,478,854 Share premium 5,672,425,121,121
Contract assets 208,515,931,997 Accumulated other comprehensive loss (6,726,079,112)
Deferred tax assets 82,270,164,199 Retained earnings 1,452,969,176,271
Other non-current financial assets 25,954,612,332
Other non-current assets 1,725,557,715 TOTAL EQUITY 7,296,603,218,280
TOTAL ASSETS 12,165,838,879,527 TOTAL LIABILITIES AND EQUITY 12,165,838,879,527

March 17, 2023

SAMSUNG BIOLOGICS CO., LTD

president & CEO John Rim

The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.

Samil PricewaterhouseCoopers CEO Soonsoo Yoon

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION